A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of Crohn's disease (CD) for at least 3 months prior to baseline
* Confirmed diagnosis of moderate to severe CD as assessed by Crohn'

Where it's running

• University of Alabama Liver Center
  Birmingham, Alabama, United States
• Del Sol Research Management, LLC
  Tucson, Arizona, United States
• Moore Clinical Trials, LLC
  Little Rock, Arkansas, United States
• Om Research LLC
  Apple Valley, California, United States
• Valley Gastroenterology Medical Group
  Arcadia, California, United States
• Southern California Research Center
  Coronado, California, United States

+406 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Janssen Research & Development, LLC Clinical Trial — Janssen Research & Development, LLC

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease

  This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.

  Recruiting Janssen Research & Development, LLC · Amiens · NCT07822529

• Colonic delivery of two antibodies to see if they reach the bloodstream in healthy people

  This early study tests whether guselkumab and adalimumab given directly into the colon can enter the body in healthy adults.

  Recruiting Phase 1 Surmount Services, Inc. · Maroochydore, Queensland · NCT07788807

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• Guselkumab in Moderate-to-Severe Ulcerative Colitis: Real-World Experience

  This real-world study tests whether guselkumab helps adults with moderate-to-severe ulcerative colitis and how safe it is for them.

  Recruiting Second Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07726888

• Guselkumab in Crohn's Disease: Optimising Care for Real-World Patients (OPTIM Study A)

  This study tests whether guselkumab can help adults with Crohn's disease, including those who have had prior therapies or partial responses, when used in real-world clinical settings.

  Recruiting Phase 4 Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Amiens · NCT07616687

• Guselkumab use in Crohn's disease and ulcerative colitis

  This study looks at how long people with moderate-to-severe Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.

  Recruiting Janssen-Cilag Pharma GmbH · Vienna · NCT07606339

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.